Summary demographic and outcome data for the GWAS cohort
| Variables . | Patient . |
|---|---|
| Number of patients | 1298 |
| Age, y | 38.2 ± 14 |
| Sex match (patient/donor), n (%) | |
| Male/male | 446 (34.3) |
| Male/female | 309 (23.8) |
| Female/male | 288 (22.2) |
| Female/female | 255 (19.7) |
| Race, n (%) | |
| White | 1116 (86.0) |
| Other | 182 (14.0) |
| Diagnosis, n (%) | |
| Acute leukemia | 465 (35.82) |
| CML | 486 (37.44) |
| MDS | 229 (17.64) |
| CLL, HD, and NHL | 79 (6.1) |
| Multiple myeloma | 39 (3.0) |
| Disease risk, n (%) | |
| Low | 361 (27.8) |
| Intermediate | 594 (45.8) |
| High | 343 (26.4) |
| Donor type, n (%) | |
| Unrelated donor | 686 (52.8) |
| Matched related donor | 612 (47.2) |
| Stem cell source | |
| BM, n (%) | 921 (71.0) |
| Peripheral blood | 377 (29.0) |
| TBI dose | |
| None, n (%) | 531 (40.9) |
| ≤ 1200 Gy | 366 (28.2) |
| > 1200 Gy | 401 (30.9) |
| aGVHD IIb-IV, n (%) | 829 (58.5) |
| aGVHD III-IV, n (%) | 323 (25.0) |
| Variables . | Patient . |
|---|---|
| Number of patients | 1298 |
| Age, y | 38.2 ± 14 |
| Sex match (patient/donor), n (%) | |
| Male/male | 446 (34.3) |
| Male/female | 309 (23.8) |
| Female/male | 288 (22.2) |
| Female/female | 255 (19.7) |
| Race, n (%) | |
| White | 1116 (86.0) |
| Other | 182 (14.0) |
| Diagnosis, n (%) | |
| Acute leukemia | 465 (35.82) |
| CML | 486 (37.44) |
| MDS | 229 (17.64) |
| CLL, HD, and NHL | 79 (6.1) |
| Multiple myeloma | 39 (3.0) |
| Disease risk, n (%) | |
| Low | 361 (27.8) |
| Intermediate | 594 (45.8) |
| High | 343 (26.4) |
| Donor type, n (%) | |
| Unrelated donor | 686 (52.8) |
| Matched related donor | 612 (47.2) |
| Stem cell source | |
| BM, n (%) | 921 (71.0) |
| Peripheral blood | 377 (29.0) |
| TBI dose | |
| None, n (%) | 531 (40.9) |
| ≤ 1200 Gy | 366 (28.2) |
| > 1200 Gy | 401 (30.9) |
| aGVHD IIb-IV, n (%) | 829 (58.5) |
| aGVHD III-IV, n (%) | 323 (25.0) |
aGVHD indicates acute graft versus host disease; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; GWAS, genome-wide association study; HD, Hodgkin's disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; and TBI, total body irradiation.